Risultati di ricerca
Benvenuti nel sito dell’A.M.L di Montemarciano La lega fantacalcistica più grande delle Marche… e non solo
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012 Feb;13 (2):207-14. doi: 10.1016/S1470-2045 (11)70326-6. Epub 2011 Dec 22.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
23 dic 2011 · In a post-hoc analysis of the AML96 study, we investigated whether we could define prognostic and predictive groups with significantly different probabilities of post-remission survival for patients with AML who were treated with high-dose cytarabine, or autologous or allogeneic HSCT in a priority-based and risk-adapted manner.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
12 ago 2010 · We present an analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years. The AML96 trial included 909 patients with a median age of 67 years (range, 61-87 years). Treatment included cytarabine-based induction therapy followed by 1 consolidation. ….
- Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter Aulitzky, Heinrich Bodenstein, Martin B...
- 2010
31 mag 2011 · The AML96 trial included 1,862 patients ≥ 18 years old with primary and secondary or treatment-related AML and refractory anemia with excess of blasts according to the French-American-British (FAB) classification. All AML FAB subtypes were eligible for study apart from patients with acute promyelocytic leukemia (FAB M3).
- Christoph Röllig, Martin Bornhäuser, Christian Thiede, Franziska Taube, Michael Kramer, Brigitte Moh...
- 2011
12 ago 2010 · A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial | Blood | American Society of Hematology. CLINICAL TRIALS AND OBSERVATIONS | August 12, 2010.
1 feb 2012 · In the multicentre AML96 trial, 586 patients (aged 15–60 years) with AML—excluding those with t (8;21)—who were in complete remission after double induction treatment were consolidated with allogeneic HSCT, autologous HSCT, or chemotherapy containing high-dose cytarabine in a priority-based and risk-adapted manner.
